Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Détail de l'auteur
Auteur Xiaoping NING |
Documents disponibles écrits par cet auteur (1)
Faire une suggestion Affiner la recherche
Risperidone Dosing in Children and Adolescents with Autistic Disorder: A Double-Blind, Placebo-Controlled Study / Justine M. KENT in Journal of Autism and Developmental Disorders, 43-8 (August 2013)
[article]
Titre : Risperidone Dosing in Children and Adolescents with Autistic Disorder: A Double-Blind, Placebo-Controlled Study Type de document : Texte imprimé et/ou numérique Auteurs : Justine M. KENT, Auteur ; Stuart KUSHNER, Auteur ; Xiaoping NING, Auteur ; Keith KARCHER, Auteur ; Seth NESS, Auteur ; Michael G. AMAN, Auteur ; Jaskaran SINGH, Auteur ; David HOUGH, Auteur Article en page(s) : p.1773-1783 Langues : Anglais (eng) Mots-clés : Autistic disorder Double-blind Placebo-controlled Risperidone Index. décimale : PER Périodiques Résumé : Efficacy and safety of 2 risperidone doses were evaluated in children and adolescents with autism. Patients (N = 96; 5–17 years), received risperidone (low-dose: 0.125 mg/day [20 to 45 kg], 0.175 mg/day [45 kg] or high-dose: 1.25 mg/day [20 to 45 kg], 1.75 mg/day [45 kg]) or placebo. Mean baseline (range 27–29) to endpoint change in Aberrant Behavior Checklist-Irritability (primary endpoint) was significantly greater in the high-dose—(?12.4 [6.5]; p 0.001), but not low-dose (?7.4 [8.1]; p = 0.164) group, versus placebo (?3.5 [10.7]). Clinical Global Impressions-Severity and Children’s Yale-Brown Obsessive Compulsive Scale scores improved significantly only in the high-dose group, consistent with ABC-I results. Somnolence, sedation and increased appetite occurred more frequently in high-versus low-dose groups. Overall, increased appetite occurred most frequently. En ligne : http://dx.doi.org/10.1007/s10803-012-1723-5 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=205
in Journal of Autism and Developmental Disorders > 43-8 (August 2013) . - p.1773-1783[article] Risperidone Dosing in Children and Adolescents with Autistic Disorder: A Double-Blind, Placebo-Controlled Study [Texte imprimé et/ou numérique] / Justine M. KENT, Auteur ; Stuart KUSHNER, Auteur ; Xiaoping NING, Auteur ; Keith KARCHER, Auteur ; Seth NESS, Auteur ; Michael G. AMAN, Auteur ; Jaskaran SINGH, Auteur ; David HOUGH, Auteur . - p.1773-1783.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 43-8 (August 2013) . - p.1773-1783
Mots-clés : Autistic disorder Double-blind Placebo-controlled Risperidone Index. décimale : PER Périodiques Résumé : Efficacy and safety of 2 risperidone doses were evaluated in children and adolescents with autism. Patients (N = 96; 5–17 years), received risperidone (low-dose: 0.125 mg/day [20 to 45 kg], 0.175 mg/day [45 kg] or high-dose: 1.25 mg/day [20 to 45 kg], 1.75 mg/day [45 kg]) or placebo. Mean baseline (range 27–29) to endpoint change in Aberrant Behavior Checklist-Irritability (primary endpoint) was significantly greater in the high-dose—(?12.4 [6.5]; p 0.001), but not low-dose (?7.4 [8.1]; p = 0.164) group, versus placebo (?3.5 [10.7]). Clinical Global Impressions-Severity and Children’s Yale-Brown Obsessive Compulsive Scale scores improved significantly only in the high-dose group, consistent with ABC-I results. Somnolence, sedation and increased appetite occurred more frequently in high-versus low-dose groups. Overall, increased appetite occurred most frequently. En ligne : http://dx.doi.org/10.1007/s10803-012-1723-5 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=205